SWM
CYCN icon

Spire Wealth Management’s Cyclerion Therapeutics CYCN Stock Holding History

Spire Wealth Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-54
Closed -$1K – 2497
2022
Q4 		$1K Buy
+54
New +$639 ﹤0.01% 2158
2022
Q1 		– Sell
-54
Closed -$2K – 2598
2021
Q4 		$2K Buy
+54
New +$2.55K ﹤0.01% 2766

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Spire Wealth Management's CYCN Position: Q1 2023 in Review

Spire Wealth Management sold out of Cyclerion Therapeutics (CYCN) in Q1 2023, closing a stake of 54 shares — an estimated $1K sold.

Spire Wealth Management first reported a position in CYCN in Q4 2021 and held it in 2 quarters. The position peaked at $2K in Q4 2021. 34 funds tracked by Wall St. Rank hold CYCN as of Q1 2023.

  • Spire Wealth Management reported no remaining Cyclerion Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Spire Wealth Management sold 54 Cyclerion Therapeutics shares in Q1 2023, an estimated $1K.
  • Spire Wealth Management first reported a position in Cyclerion Therapeutics in Q4 2021 and held it in 2 quarters.
  • Spire Wealth Management's Cyclerion Therapeutics position peaked at $2K in Q4 2021.
  • 34 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2023.

Based on Spire Wealth Management's 13F filing for Q1 2023, filed 9 May 2023.